SCHEMBL9629153

SCHEMBL9629153

O=c1c2c(c3cccnc3n1-c1ccccc1)SCC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 1/20 0.50
PDE4A P27815 8/20 0.49
PDE4B Q07343 6/20 0.49
PDE4C Q08493 6/20 0.49
PDE4D Q08499 6/20 0.49
ALDH1A1 P00352 2/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
PDE1B Q01064 2/20 0.43
PDE1A P54750 1/20 0.43
KAT2B Q92831 1/20 0.41
LDHA P00338 1/20 0.41
LOXL3 P58215 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
PDE11A Q9HCR9 3/20 0.39
PDE2A O00408 2/20 0.38
PDE6C P51160 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10377552 0.89 KAT2B (0.44) FEN1PDE4APDE4BPDE4CPDE4D
SCHEMBL10379085 0.89 ALDH1A1 (0.45) FEN1PDE4APDE4BPDE4CPDE4D
SCHEMBL10377395 0.89 HPGD (0.44) FEN1PDE4APDE4BPDE4CPDE4D
SCHEMBL10379090 0.87 MAPT (0.46) FEN1PDE4APDE4BPDE4CPDE4D
SCHEMBL10378837 0.86 MAPT (0.38) FEN1PDE4APDE4BPDE4CPDE4D
SCHEMBL10378764 0.86 KAT2B (0.48) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL10377150 0.85 FEN1 (0.41) FEN1PDE4APDE4BPDE4CPDE4D
SCHEMBL10376581 0.84 KAT2B (0.49) PDE4BPDE4DTSHRKAT2BMAPT
SCHEMBL10379093 0.83 KAT2B (0.47) PDE4BPDE4DALDH1A1CYP2C19KAT2B
SCHEMBL10655441 0.83 PDE4B (0.42) PDE4BPDE4DALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0338010-B1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1992-02-05 EP claimed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP claimed
EP-0338010-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE. SCHERING CORP (US) 1989-10-25 EP claimed
WO-1988004172-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1988-06-16 WO claimed
EP-0127135-B1 FUSED TRICYCLIC DERIVATIVES OF NAPHTHYRIDINONE AND PYRIDONE AND THE CORRESPONDING THIONES SCHERING CORPORATION (US) 1990-08-29 EP disclosed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP disclosed
EP-0338010-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE. SCHERING CORP (US) 1989-10-25 EP disclosed
US-4801589-A QUINOLINE, NAPHTHYRIDINE, AND PYRIDO-PYRAZINE DERIVATIVES SCHERING CORPORATION (US) 1989-01-31 US disclosed
WO-1988004172-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1988-06-16 WO disclosed
US-4740511-A ANTIALLERGENS, ANTIINFLAMMATORY, ANTIULCER AGENTS SCHERING CORPORATION (US) 1988-04-26 US disclosed
US-4680298-A Tricyclic anti-allergy and use as anti-inflammatory agents SCHERING CORPORATION (US) 1987-07-14 US disclosed
US-4680297-A Tricyclic positive inotropic agents SCHERING CORPORATION (US) 1987-07-14 US disclosed
EP-0127135-A2 Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones SCHERING CORPORATION (US) 1984-12-05 EP disclosed